{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:40:29Z","timestamp":1775151629807,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T00:00:00Z","timestamp":1361318400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2334-13-92","type":"journal-article","created":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T20:51:34Z","timestamp":1361393494000},"source":"Crossref","is-referenced-by-count":9,"title":["A longitudinal evaluation of the impact of a polylactic acid injection therapy on health related quality of life amongst HIV patients treated with anti-retroviral agents under real conditions of use"],"prefix":"10.1186","volume":"13","author":[{"given":"Martin","family":"Duracinsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew Richard","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Dolivo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Mouly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Chassany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,20]]},"reference":[{"issue":"11","key":"2289_CR1","first-page":"760","volume":"1","author":"JF Delfraissy","year":"2004","unstructured":"Delfraissy JF: Prise en charge th\u00e9rapeutique des personnes infect\u00e9es par le VIH: recommandations du groupe d\u2019experts. Sidanet. 2004, 1 (11): 760-Published Full Text: http:\/\/www.trt-5.org\/IMG\/pdf\/avis_CEPP_2004.pdf","journal-title":"Sidanet"},{"key":"2289_CR2","doi-asserted-by":"publisher","first-page":"886","DOI":"10.4267\/10608\/2023","volume":"17","author":"M Saves","year":"2001","unstructured":"Saves M, Mercie P, Ch\u00eane G: Syndrome lipodystrophique et traitements antir\u00e9troviraux chez les patients infect\u00e9s parle VIH-1. M\u00e9decine\/sciences. 2001, 17: 886-892.","journal-title":"M\u00e9decine\/sciences"},{"issue":"1","key":"2289_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2165\/00002018-200023010-00004","volume":"23","author":"GM Behrens","year":"2000","unstructured":"Behrens GM, Stoll M, Schmidt RE: Lipodystrophy syndrome in HIV infection: what is it, what can it and how can it be managed?. Drug Saf. 2000, 23 (1): 57-76. 10.2165\/00002018-200023010-00004.","journal-title":"Drug Saf"},{"issue":"4","key":"2289_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/00126334-200212010-00006","volume":"31","author":"J Blanch","year":"2002","unstructured":"Blanch J, Rousaud A, Martinez E, De Lazzari E, Peri JM, Milinkovic A, Perez-Cuevas JB, Blanco JL, Gatell JM: Impact of lipodystrophy on the quality of life of HIV-1-infected patients. J Acquir Immune Defic Syndr. 2002, 31 (4): 404-407. 10.1097\/00126334-200212010-00006.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2289_CR5","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","volume":"353","author":"A Carr","year":"1999","unstructured":"Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA: Diagnosis, prediction and natural course of HIV- 1 protease-inhibitor-associated-lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999, 353: 2093-2099. 10.1016\/S0140-6736(98)08468-2.","journal-title":"Lancet"},{"issue":"10","key":"2289_CR6","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1086\/339866","volume":"34","author":"M Saves","year":"2002","unstructured":"Saves M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, Basdevant A, Leport C, Chene G, Antiproteases Cohorte (APROCO) Study Group: Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002, 34 (10): 1396-1405. 10.1086\/339866.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2289_CR7","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1517\/13543784.10.8.1443","volume":"10","author":"MA Garcia-Viejo","year":"2001","unstructured":"Garcia-Viejo MA, Ruiz M, Martinez E: Strategies for treating HIV-related lipodystrophy. Expert Opin Investig Drugs. 2001, 10 (8): 1443-1456. 10.1517\/13543784.10.8.1443.","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"2289_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2165\/00002018-200124030-00001","volume":"24","author":"E Martinez","year":"2001","unstructured":"Martinez E, Garcia-Viejo MA, Blanch L, Gatell JM: Lipodystrophy syndrome in patients with HIV infection: quality of life issues. Drug Saf. 2001, 24 (3): 157-166. 10.2165\/00002018-200124030-00001.","journal-title":"Drug Saf"},{"issue":"18","key":"2289_CR9","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1097\/00002030-200112070-00012","volume":"15","author":"S Duran","year":"2001","unstructured":"Duran S, Saves M, Spire B, Cailleton V, Sobel A, Carrieri P, Salmon D, Moatti JP, Leport C, APROCO Study Group: Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001, 15 (18): 2441-2444. 10.1097\/00002030-200112070-00012.","journal-title":"AIDS"},{"issue":"5","key":"2289_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/QAI.0b013e318245cafe","volume":"59","author":"M Duracinsky","year":"2012","unstructured":"Duracinsky M, Herrmann S, Berzins B, Armstrong AR, Kohli R, Le Coeur S, Diouf A, Fournier I, Schechter M, Chassany O: The development of PROQOL-HIV: An international instrument to assess the health-related quality of life of persons living with HIV\/AIDS. J Acquir Immune Defic Syndr. 2012, 59 (5): 498-505. 10.1097\/QAI.0b013e318245cafe.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2289_CR11","first-page":"994","volume":"51","author":"Recommandations concernant le traitement anti-VIH","year":"2001","unstructured":"Recommandations concernant le traitement anti-VIH: Sous-commission clinique de la Commission F\u00e9d\u00e9rale concernant les questions relatives au VIH-Sida. Bulletin. 2001, 51: 994-1000.","journal-title":"Bulletin"},{"issue":"17","key":"2289_CR12","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1097\/00002030-200311210-00009","volume":"17","author":"MA Valantin","year":"2003","unstructured":"Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H, Bousquet R, Katz P, Costagliola D, Katlama C: Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS. 2003, 17 (17): 2471-2477. 10.1097\/00002030-200311210-00009.","journal-title":"AIDS"},{"key":"2289_CR13","unstructured":"Commission d\u2019evaluation des produits et prestations Republique Fran\u00e7ais: NEW-FILL, acide L-polylactique. 31 Mars 2004. Publisher Full Text: http:\/\/www.trt-5.org\/IMG\/pdf\/avis_CEPP_2004.pdf"},{"issue":"Supp 1","key":"2289_CR14","first-page":"189","volume":"25","author":"M Duracinsky","year":"2004","unstructured":"Duracinsky M, Cervoni J, Vincent V, Lascoux C, Bourgarit A, Acquadro C, Conway K, Wu A, Chassany O: Validation d'un questionnaire de qualit\u00e9 de vie sp\u00e9cifique de la lipodystrophie li\u00e9e \u00e0 la pathologie VIH. La Revue de M\u00e9decine Interne. 2004, 25 (Supp 1): 189-","journal-title":"La Revue de M\u00e9decine Interne"},{"key":"2289_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11136-005-8342-y","volume":"15","author":"G Guaraldi","year":"2006","unstructured":"Guaraldi G, Orlando G, Murri R, Vandelli M, De Paola M, Beghetto B, Nardini G, Ciaffi S, Vichi F, Esposito , Wu AW: Quality of life and body image in the assessment of psychological impact of lipodystrophy: validation of the italian version of assessment of body change and distress questionnaire. Qual Life Res. 2006, 15: 173-178. 10.1007\/s11136-005-8342-y.","journal-title":"Qual Life Res"},{"key":"2289_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0895-4356(94)90036-1","volume":"47","author":"EF Juniper","year":"1994","unstructured":"Juniper EF, Guyatt GH, Willan A, Griffith LE: Determining the minimal important change in a disease-specific QoL questionnaire. J Clin Epidemiol. 1994, 47: 81-87. 10.1016\/0895-4356(94)90036-1.","journal-title":"J Clin Epidemiol"},{"key":"2289_CR17","unstructured":"World Medical Association: Declaration of Helsinki. http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html (accessed April 4, 2005)"},{"issue":"11","key":"2289_CR18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1046\/j.1524-4725.2002.02099.x","volume":"28","author":"J James","year":"2002","unstructured":"James J, Carruthers A, Carruthers J: HIV-associated facial lipoatrophy. Dermatol Surg. 2002, 28 (11): 979-986. 10.1046\/j.1524-4725.2002.02099.x.","journal-title":"Dermatol Surg"},{"key":"2289_CR19","volume-title":"statistical analysis software [computer program]","author":"SAS","year":"2002","unstructured":"SAS: statistical analysis software [computer program]. 2002, Cary (NC): SAS Institute"},{"issue":"5","key":"2289_CR20","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/QAI.0b013e31824be3f2","volume":"59","author":"M Duracinsky","year":"2012","unstructured":"Duracinsky M, Lalanne C, Le Coeur S, Herrmann S, Berzins B, Armstrong AR, Lau J, Fournier-Nicolle I, Sow S, Chassany O: Psychometric validation of the PROQOL-HIV questionnaire, a new health-related quality of life instrument specific to HIV disease. J Acquir Immune Defic Syndr. 2012, 59 (5): 506-515. 10.1097\/QAI.0b013e31824be3f2.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2289_CR21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/01.qai.0000152834.02912.98","volume":"38","author":"M Lafaurie","year":"2005","unstructured":"Lafaurie M, Dolivo M, Porcher R, Rudant J, Madelaine I, Molina J: Treatment of facial lipoatrophy with intradermal injections of polyactic acid in HIV-infected patients. J Acquir Immune Defic Syndr. 2005, 38: 393-398. 10.1097\/01.qai.0000152834.02912.98.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"2289_CR22","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/135965350501000606","volume":"10","author":"G Guaraldi","year":"2005","unstructured":"Guaraldi G, Orlando G, De Fazio D, De Lorenzi I, Rottino A, De Santis G, Pedone A, Spaggiari A, Baccarani A, Borghi V, Esposito R: Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study. Antivir Ther. 2005, 10 (6): 753-759.","journal-title":"Antivir Ther"},{"issue":"6","key":"2289_CR23","first-page":"351","volume":"10","author":"DJ Signorini","year":"2011","unstructured":"Signorini DJ, Netto AM, Gabbay S, Monteiro MC, Signorini DH, Andrade MD, Bastos FI, Code\u00e7o CT: A comparison of sonographic assessments and clinical questionnaire in the diagnosis of HIV-associated lipodystrophy. JIAPAC. 2011, 10 (6): 351-356.","journal-title":"JIAPAC"},{"key":"2289_CR24","doi-asserted-by":"crossref","unstructured":"Mole B, Gillaizeau F, Carbonnel E, Pierre I, Brazille P, Grataloup C, Mercier S, Duracinsky M, Weiss L, Piketty C: Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: results of the LIPOPHILL open-label study. AIDS Res Hum Retroviruses. Epub ahead of print Aug 2011","DOI":"10.1089\/aid.2011.0042"},{"issue":"12","key":"2289_CR25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1089\/apc.2006.20.829","volume":"20","author":"E Negredo","year":"2006","unstructured":"Negredo E, Higueras C, Adell X, Martinez JC, Martinez E, Puig J, Fumaz CR, Mu\u00f1oz-Moreno JA, Perez-Alvarez N, Videla S, Estany C, Cinquegrana D, Gonzalez-Mestre V, Clotet B: Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances. AIDS Patient Care STDS. 2006, 20 (12): 829-837. 10.1089\/apc.2006.20.829.","journal-title":"AIDS Patient Care STDS"},{"issue":"5 Pt 1","key":"2289_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0151-9638(06)70933-4","volume":"133","author":"I Bodokh","year":"2006","unstructured":"Bodokh I, Simonet P: Polylactic acid injections (Newfill) in the treatment of facial lipodystrophy in HIV-positive patients. Ann Dermatol Venereol. 2006, 133 (5 Pt 1): 429-432.","journal-title":"Ann Dermatol Venereol"},{"issue":"5","key":"2289_CR27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/QAI.0b013e318158bec9","volume":"46","author":"DL Carey","year":"2007","unstructured":"Carey DL, Baker D, Rogers GD, Petoumenos K, Chuah J, Easey N, Machon K, Cooper DA, Emery S, Carr A, Facial LipoAtrophy Study in HIV Investigators: A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy. J Acquir Immune Defic Syndr. 2007, 46 (5): 581-589. 10.1097\/QAI.0b013e318158bec9.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"2289_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1468-1293.2008.00667.x","volume":"10","author":"D Carey","year":"2009","unstructured":"Carey D, Baker D, Petoumenos K, Chuah J, Rogers GD, Watson J, Cooper DA, Emery S, Carr A: FLASH investigators. Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up. HIV Med. 2009, 10 (3): 163-172. 10.1111\/j.1468-1293.2008.00667.x.","journal-title":"HIV Med"},{"issue":"11","key":"2289_CR29","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1089\/apc.2007.0029","volume":"21","author":"G Orlando","year":"2007","unstructured":"Orlando G, Guaraldi G, De Fazio D, Rottino A, Grisotti A, Blini M, De Santis G, Pedone A, Spaggiari A, Baccarani A, Vandelli M, De Paola M, Comelli D, Nardini G, Beghetto B, Squillace N, Esposito R: Long-term psychometric outcomes of facial lipoatrophy therapy: forty-eight-week observational, nonrandomized study. AIDS Patient Care STDS. 2007, 21 (11): 833-842. 10.1089\/apc.2007.0029.","journal-title":"AIDS Patient Care STDS"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-13-92\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-92.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-92","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-92.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T17:36:33Z","timestamp":1688060193000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-13-92"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,20]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2289"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-13-92","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,20]]},"article-number":"92"}}